Opinion|Videos|November 18, 2026

Interpreting Subgroup Analyses

Subgroup analyses from the RASolute 302 trial of daraxonrasib in metastatic pancreatic cancer raise questions about specific RAS alleles.

Subgroup analyses from the RASolute 302 trial of daraxonrasib in metastatic pancreatic cancer raise questions about specific RAS alleles. Jonathan Lee, MD, acknowledges that tumors with Q61 and certain other alleles may respond less well; however, he prefers giving patients the benefit of the doubt with this oral targeted therapy. He frames the decision as a shared conversation, noting that few patients reach third-line or fourth-line treatment. Paul E. Oberstein, MD, views subgroups as hypothesis generating, warns that response rate and progression-free survival in groups of 10 to 15 patients can mislead, and calls overall survival king. Shiraj Sen, MD, PhD, points out that every subgroup in the published forest plot favored daraxonrasib, consistency he rarely sees in pancreatic cancer, including patients with and without liver metastases. Dr. Sen wants more data on RAS G12 vs non-G12 tumors and specific alleles, and he expects ongoing late-phase combination studies, including a RAS G12D inhibitor with daraxonrasib, to keep evolving the standard of care.


Related to this article